Companies Forum

an opportunity to network and collaborATE

CRDN Companies Forum meetings welcome representatives from pharmaceutical, biotechnology and healthcare companies operating in the rare disease space who are interested in understanding the regulatory environment for orphan medicinal products and working collaboratively on projects. 

Meetings are conducted under Chatham House Rules and held  three times a year. Content for discussion is agreed amongst the group and high calibre speakers sourced by CRDN. Meetings are a half to full day,  informative, relaxed and collaborative and members receive presented slides and minutes of the meeting for future reference.

COMPANIES FORUM MEMBERS INCLUDE:

Abcam logo
Alexion logo
Atlantic research group logo
Congenica Logo
EAHSN master logo
Healx Logo
Illumina logo
lifearc logo
Pfizer logo
pulse infoframe logo
SOBI logo
Takeda logo
Bionical Emas logo CRDN companies Forum

PREVIOUS COMPANIES FORUM MEETINGS:

SPRING 2020 MEETING - 6 MAR

Venue: 
Royal Society of Medicine, London

Speakers: 
Prof Ron Akehurst –  University of Sheffield
Sheela Upadhyaya – HST and Topic Selection Specialist.  National Institute for Health and Care Excellence

AUTUMN 2019 MEETING - 29 NOV

Venue:
Royal Society of Medicine, London 

Speakers:
Prof Chas Bountra – University of Oxford Dan Lewi – CATs Foundation
Tess Harris – PKD  UK
Allison Watson – Ring20

2021 MEETINGS

We’ve taken CF meetings online for the time being. More details coming soon…

WATCH OUR LATEST VIDEO

Owen Marks, Head of Rare Disease at Pfizer after attending Cambridge Rare Disease Network (CRDN) virtual Companies Forum – an interesting discussion on rare disease clinical trials and learnings from the pandemic.

RECOMMENDED READING

CAN COMPANIES FORUM 2020 CONNECT THE DOTS?

Read CRDN’s blog exploring how our Companies Forum is seeking to challenge the status quo in orphan therapeutic development and support companies to connect the dots.

pharmaphorum logo

Pharmaphorum’s George Underwood talks to CRDN Companies Forum lead Dr. Ron Jortner about the biggest challenges facing rare disease pharma, and how the industry can tackle them.

Atarim

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

CRDN sign up to newsletter

Sign up to our monthly newsletter packed with news & events. Join our thriving rare disease community.

 

You have Successfully Subscribed!